Pfizer has stopped developing a once-daily pill to treat obesity after a person in a clinical trial showed signs of a ...

Pfizer (NYSE:PFE) recently announced the cessation of Danuglipron's development, an event that coincided with a 3% decline in ...

Pfizer (NYSE: PFE) recently reminded investors how risky the drug-development business can be. On April 14, the company told investors it would scrap development of danuglipron, its oral GLP-1 ...

Europe's pharma sector now trails the US, it went on to say, "on every investor metric from availability of capital, intellectual property, speed of approval to rewards for innovation", and even ...

Pfizer is facing patent expirations for several ... In addition to competing treatments, Vyndaqel is expected to face generic competition in the U.S. in 2028. Drug developers need to communicate ...

Johnson & Johnson’s Joaquin Duato is no longer the highest paid CEO in pharma. Meanwhile, just two women make the top 10.

Playing both sides of trade war, pharma companies are asking for certain compensations for scientific innovation and a ...

After the world’s largely disastrous response to the coronavirus, countries tasked the WHO with overseeing a pandemic treaty in 2021; negotiations concluded early Wednesday on an agreement expected to ...

PARIS (Reuters) -Nearly three dozen global pharmaceutical companies, in a letter to the head of the European Commission, ...

A review of 600 US patients treated for suspected sepsis found 31.5% most likely didn't have a bacterial infection, while ...